Asparkamas

In the complex therapy of the following diseases and conditions:

heart failure,

CHD,

hypokalemia,

heart rhythm disorders (including myocardial infarction, overdose of cardiac glycosides).

As an additional tool:

chronic heart diseases (heart failure, a condition after a myocardial infarction),

heart rhythm disorders (primarily ventricular arrhythmias),

treatment with cardiac glycosides,

replacement therapy for magnesium/potassium deficiency in food.

Arrhythmias, heart failure on the background of hypokalemia, angina, hypokalemia (indomitable vomiting, diarrhea, prolonged treatment with digitalis glycosides, corticosteroids and diuretics).

Hypokalemia. As an auxiliary agent for heart failure, myocardial infarction, heart rhythm disorders (including arrhythmias caused by an overdose of cardiac glycosides), hypomagnesemia.

acute and chronic renal failure,

hyperkalemia.

hypersensitivity to any of the components of the drug,

acute and chronic renal failure,

hyperkalemia,

hypermagnesemia,

Addison's disease,

AV-block I–III degree,

cardiogenic shock (BP <90 mmHg)),

violation of amino acid metabolism,

severe myasthenia gravis,

hemolysis,

acute metabolic acidosis,

dehydration.

With caution: pregnancy (especially the first trimester), lactation.

Hypersensitivity, renal failure, oliguria, anuria, hyperkalemia, impaired amino acid metabolism, heart block, hypotension, severe myasthenia gravis, Addison's disease, hemolysis.

Severe renal impairment, hyperkalemia, hypermagnesemia, adrenal insufficiency, shock, AV block, severe myasthenia gravis, dehydration, hypersensitivity to sorbitol.

Possible nausea, unpleasant sensations or burning in the epigastric region (with cholecystitis and anacid gastritis). These phenomena usually pass with a decrease in the dose of the drug.

Possible nausea, vomiting, diarrhea, unpleasant sensations or burning in the pancreas (in patients with anacid gastritis or cholecystitis), AV block, paradoxical reaction (an increase in the number of extrasystoles), hyperkalemia (nausea, vomiting, diarrhea, paresthesia), hypermagnesemia (redness of the face, thirst, decreased blood pressure, hyporeflexia, respiratory depression, convulsions).

Bradycardia, peripheral circulatory disorders.

Symptoms of hyperkalemia and hypermagnesemia (with increased infusion rate) - muscle weakness, disorders of the central nervous system, fatigue, paresis, coma, lack of reflexes, nausea, vomiting, impaired myocardial conduction, in rare cases, an increase in the number of extrasystoles is possible.

Asparkamas is a source of potassium and magnesium ions, regulates metabolic processes. The mechanism of action is presumably associated with the role of asparaginate as a carrier of magnesium and potassium ions into the intracellular space and the participation of asparaginate in metabolic processes. Thus, Asparkamas eliminates the electrolyte imbalance, reduces the excitability and conductivity of the myocardium (moderate antiarrhythmic effect).

The most important intracellular cations To and Mg² they play a key role in the functioning of numerous enzymes, the formation of connections between macromolecules and intracellular structures, and the mechanism of muscle contractility. The intra-and extracellular ratio of potassium, calcium, sodium, and magnesium ions affects the contractility of the myocardium. Exogenous aspartate acts as an ion conductor: it has a high affinity for cells, due to the slight dissociation of its salts, ions in the form of complex compounds penetrate into the cell. Magnesium and potassium aspartates improve myocardial metabolism. Lack of magnesium / potassium predisposes to the development of hypertension, atherosclerosis of the coronary arteries, arrhythmias and metabolic changes in the myocardium

Regulates (K ions ) conducting impulses along nerve fibers, synaptic transmission, muscle contraction, the work of the heart muscle.

Due to magnesium ions, it participates in the processes of energy intake and consumption, normalizes the balance of electrolytes, and the transport of K ions , membrane permeability, neuromuscular conduction, DNA synthesis, RNA, cell growth, cell division, oxygen uptake, and phosphate synthesis (aspartic acid).

Asparkamas reduces sensitivity to cardiac glycosides.

Pharmacodynamic: concomitant use with potassium-sparing diuretics (triamterene, spironolactone), beta-blockers, cyclosporine, heparin, ACE inhibitors, NSAIDs increases the risk of hyperkalemia up to the development of arrhythmia and asystole. The use of potassium preparations together with GCS eliminates hypokalemia caused by the latter. Under the influence of potassium, the undesirable effects of cardiac glycosides are reduced. Enhances the negative bathmotropic effect of antiarrhythmic drugs. Anesthetics increase the inhibitory effect of magnesium preparations in the CNS, while the use of atracurium, decamethonium, succinylcholine and suxamethonium may increase the neuromuscular blockade, calcitriol increases the magnesium content in blood plasma, calcium supplements reduce the effect of magnesium preparations

Pharmacokinetic: astringents and enveloping agents reduce the absorption of the drug in the gastrointestinal tract, and it is necessary to observe a 3-hour interval between ingestion of the drug Asparkamas with the listed funds.

The risk of hyperkalemia is increased by NSAIDs, potassium-sparing diuretics, cyclosporine, beta-blockers, heparin, ACE inhibitors, hypermagnesemia-calcium preparations, neuromuscular blockade-atracuronium, decamethonium, succin chloride, suxamethonium. Magnesium reduces the effectiveness of neomycin, polymyxin B, tetracycline and streptomycin, increases the central effect of anesthetics and the toxicity of cardiac glycosides.

With the simultaneous use of potassium-sparing diuretics and/or ACE inhibitors, hyperkalemia and hypermagnesemia may develop.